ChemDiv and Berlex Announce Collaboration
News Mar 13, 2006
ChemDiv, Inc. has announced that it has entered into a discovery research collaboration with Berlex Inc., a U.S. affiliate of Schering AG, Germany. The partners will work on the discovery of potential new lead compounds against several selected GPCR targets.
Under the terms of the collaboration, ChemDiv will apply its integrated synthetic and medicinal chemistry capabilities and collaborate with Berlex's scientists in the search for new disease therapies.
"We are looking forward to the opportunity to work with Berlex and view this as further validation of our discovery chemistry expertise," said Alexander Kiselyov, Executive VP of R&D at ChemDiv, Inc.
"ChemDiv's integrated drug discovery capabilities provide an excellent fit for Berlex and we hope that our collaborative relationship will be a long-standing one."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019